Kadmon Holdings Overview
- Year Founded
-
2009
- Status
-
Acquired/Merged
- Employees
-
127
- Latest Deal Type
-
M&A
- Financing Rounds
-
12
- Investments
-
4
Kadmon Holdings General Information
Description
Kadmon Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics with a focus on inflammatory and fibrotic diseases. Its pipeline products include Belumosudil (KD025) and KD033.
Contact Information
Website
www.kadmon.comCorporate Office
- 450 East 29th Street
- New York, NY 10016
- United States
Corporate Office
- 450 East 29th Street
- New York, NY 10016
- United States
Kadmon Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kadmon Holdings Comparisons
Industry
Financing
Details
Kadmon Holdings Competitors (8)
One of Kadmon Holdings’s 8 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| BioCryst Pharmaceuticals | Corporation | Durham, NC |
Kadmon Holdings Patents
Kadmon Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026165001-A1 | Combination therapy comprising belumosudil and gusacitinib | Pending | 28-Jan-2025 | ||
| WO-2026161860-A1 | Dosing of immunocytokines for cancer treatment | Pending | 27-Jan-2025 | ||
| WO-2025184133-A1 | Methods of treating chronic graft versus host disease with belumosudil after ceasing administration of ruxolitinib | Pending | 29-Feb-2024 | ||
| US-20260315475-A1 | Method of administering belumosudil for patent subpopulations with hepatic impairment | Pending | 21-Nov-2023 | ||
| WO-2025110992-A1 | Method of administering belumosudil for patient subpopulations with hepatic impairment | Inactive | 21-Nov-2023 | A61K31/517 |
Kadmon Holdings Signals
Kadmon Holdings Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Kadmon Holdings Investments & Acquisitions (4)
Kadmon Holdings’s most recent deal was a Joint Venture with Joint Venture (Kadmon Holdings / Meiji Seika Pharma Co.). The deal was made on 26-Dec-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Joint Venture (Kadmon Holdings / Meiji Seika Pharma Co.) | 26-Dec-2019 | Joint Venture | Drug Discovery | ||
| BK Pharmaceuticals | 07-Nov-2019 | Joint Venture | Pharmaceuticals | ||
| Three Rivers Pharmaceuticals | 25-Oct-2010 | Merger/Acquisition | Pharmaceuticals | ||
| PhytoCeutica | 24-Oct-2010 | Merger/Acquisition | Biotechnology |
Kadmon Holdings FAQs
-
When was Kadmon Holdings founded?
Kadmon Holdings was founded in 2009.
-
Where is Kadmon Holdings headquartered?
Kadmon Holdings is headquartered in New York, NY.
-
What is the size of Kadmon Holdings?
Kadmon Holdings has 127 total employees.
-
What industry is Kadmon Holdings in?
Kadmon Holdings’s primary industry is Drug Discovery.
-
Is Kadmon Holdings a private or public company?
Kadmon Holdings is a Private company.
-
What is the current valuation of Kadmon Holdings?
The current valuation of Kadmon Holdings is .
-
What is Kadmon Holdings’s current revenue?
The current revenue for Kadmon Holdings is .
-
How much funding has Kadmon Holdings raised over time?
Kadmon Holdings has raised $129M.
-
Who are Kadmon Holdings’s investors?
72 KDMN Investment, Aeon Group (Miami), GoldenTree Asset Management, Jiangsu Tech Industry Investment, and Palkon Capital Management are 5 of 9 investors who have invested in Kadmon Holdings.
-
Who are Kadmon Holdings’s competitors?
Sarepta Therapeutics, uniQure, Genetix Biotherapeutics, Sangamo Therapeutics, and BioCryst Pharmaceuticals are some of the 8 competitors of Kadmon Holdings.
-
When was Kadmon Holdings acquired?
Kadmon Holdings was acquired on 09-Nov-2021.
-
Who acquired Kadmon Holdings?
Kadmon Holdings was acquired by Sanofi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process